– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...
Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...
RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...
Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...
Biomea Fusion (BMEA) announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company’s investigational covalent FLT3 inhibitor developed using the proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback